Search - tctmd.com

Displaying 41 - 60 of 815

Sort: Relevancy | Date

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

News Daily News

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Michael O'Riordan

February 24, 2025

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Use of Secondary CVD Prevention Meds Still Meager Worldwide

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

February 03, 2025

January 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

January 24, 2025

Athletes’ Hearts Also Require Careful Scrutiny, New Review Suggests

News Daily News

Athletes’ Hearts Also Require Careful Scrutiny, New Review Suggests

Yael L. Maxwell

January 17, 2025

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

December 06, 2024

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

News Daily News

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

December 04, 2024

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

News Daily News

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

November 27, 2024

November 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

November 26, 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

November 21, 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

News Daily News

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

November 13, 2024

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.